FedEx Corporation vs Johnson & Johnson: Strategic Comparison

This in-depth comparison examines FedEx Corporation and Johnson & Johnson across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching FedEx Corporation on its own, evaluating Johnson & Johnson, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between FedEx Corporation and Johnson & Johnson is widest.

On the headline numbers, FedEx Corporation reports annual revenue of $94.7B against $94.2B for Johnson & Johnson, while their respective market capitalizations stand at $56.0B and $612.8B. FedEx Corporation is headquartered in United States and Johnson & Johnson operates from United States, and those different home markets shape how each company competes.

FedEx Corporation: FedEx is a logistics infrastructure company. Its value comes from the ability to move millions of shipments through a time-sensitive network while giving customers visibility, customs support, and reliable delivery options.

Johnson & Johnson: Johnson & Johnson began as a medical-products company in the nineteenth century and became a diversified healthcare giant. After the Kenvue separation, it is a more focused healthcare company centered on medicine and medical technology.

FedEx Corporation and Johnson & Johnson pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between FedEx Corporation and Johnson & Johnson.

FedEx Corporation business model: FedEx's business model is a high-fixed-cost network model. The company invests in aircraft, hubs, sortation facilities, vehicles, technology, delivery density, and service providers, then earns revenue from moving high volumes of packages and freight through that network. Yield, fuel surcharges, shipment mix, route density, labor cost, and service reliability determine profitability.

Johnson & Johnson business model: Johnson & Johnson makes money by discovering, developing, manufacturing, and selling prescription medicines and medical technologies. Innovative Medicine sells therapies in oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism. MedTech sells surgery, orthopaedics, cardiovascular, and vision products to hospitals, physicians, and healthcare systems.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of FedEx Corporation stack up against those of Johnson & Johnson.

FedEx Corporation competitive advantage: FedEx's advantage is the scale and reach of its global transportation network. Aircraft, hubs, sort centers, delivery routes, tracking systems, customer relationships, customs expertise, and brand trust are difficult to replicate quickly.

Johnson & Johnson competitive advantage: Johnson & Johnson's advantage comes from scale, R&D depth, global regulatory capability, major oncology and immunology franchises, MedTech breadth, and a large commercial infrastructure.

Future prospects matter as much as current results. The growth strategies below explain how FedEx Corporation and Johnson & Johnson each plan to expand from here.

FedEx Corporation growth strategy: FedEx's growth strategy focuses on integrated air-ground operations, better yield management, international priority and freight lanes, e-commerce delivery efficiency, data-driven routing, and separating FedEx Freight so the less-than-truckload business can pursue a clearer capital-market identity.

Johnson & Johnson growth strategy: The company is investing in oncology, immunology, neuroscience, cardiovascular MedTech, electrophysiology, surgery, R&D, acquisitions, and global commercial execution.

A closer look at the financial trajectory of FedEx Corporation and Johnson & Johnson rounds out the comparison.

FedEx Corporation: FedEx reported FY2026 revenue of $94.720 billion, up 8% from FY2025, and consolidated net income of $4.433 billion. Revenue growth was supported by improved package yields, higher U.S. domestic package volume, fuel surcharges, favorable exchange rates, and international freight growth, partly offset by the expiration of the USPS contract and freight softness.

Johnson & Johnson: Johnson & Johnson's FY2025 sales increased 6.0% to $94.193 billion. Net earnings rose to $26.804 billion, helped by operating performance and other income items. Innovative Medicine generated $60.401 billion in sales, while MedTech generated $33.792 billion.